JPRN-jRCT2031260297 Serplulimab PD-L1 positive Gastroesophageal junction adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready landscape. This focused report examines JPRN-jRCT2031260297—Perioperative HLX10 (serplulimab) with S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma: A Randomized Phase 2 Investigator-Initiated Trial—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why JPRN-jRCT2031260297 is a hot trial to watch

PD-L1 positive Gastroesophageal junction adenocarcinoma is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. JPRN-jRCT2031260297 is notable because it evaluates Serplulimab in a Phase 2 design while Pathological complete response (pCR) rate by central pathology review serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The phase label is only the starting point. Allocation is Randomized, masking is Double, and the intervention model is Parallel Assignment. Planned enrollment of 136 participants across South Korea, Japan shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• Primary: Pathological complete response (pCR) rate by central pathology review
• Primary: 病理中央診断による病理学的完全奏効割合
• Secondary: Investigator-assessed event-free survival, Overall survival (OS), Major pathological response (MPR) rate by central pathology review, Investigator-assessed pCR rate, Investigator-assessed MPR rate, Investigator-assessed objective response rate (ORR), Investigator-assessed disease-free survival (DFS), Neoadjuvant treatment completion rate, Curative resection rate, Treatment completion rate up to surgery, Postoperative adjuvant treatment completion rate, Perioperative treatment completion rate, Incidence of adverse events, Incidence of serious adverse events, Pharmacokinetics (PK), Immunogenicity
• Secondary: 施設判定による無イベント生存期間、 全生存期間、 病理中央診断による病理学的奏効割合、 施設判定による病理学的完全奏効割合、 施設判定による病理学的奏効割合、 施設判定による客観的奏効割合、 施設判定による無病生存期間、 術前補助療法の完遂割合、 根治切除割合、 手術までの治療完遂割合、 術後補助療法の完遂割合、 周術期治療の完遂割合、 有害事象発現割合、 重篤な有害事象発現割合、 薬物動態、 免疫原性

Benchmark readouts in the surrounding field

• A Phase 2 Trial of Neoadjuvant Chemoradiation With Pembrolizumab Followed by Pembrolizumab With Lenvatinib in Esophageal/Gastroesophageal Junction Squamous Cell and Adenocarcinomas (Phase 2): pCR = 0 Participants
• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of RDX-002 on Postprandial Triglycerides in Patients Discontinuing the Glucagon-like Peptide-1 (GLP-1) Agonists, Semaglutide, or Tirzepatide for the Treatment of Obesity (Phase 2): Incremental Postprandial Triglycerides (TG)(Mean) = 43.81 percent change (Standard Deviation, 92.373); Incremental Postprandial Triglycerides (TG)(Mean) = -51.91 percent change (Standard Deviation, 72.293)
• A Phase II Study to Evaluate the Delay in Ovulation Following Oral Levonorgestrel Plus Meloxicam Compared to Placebo in Obese But Normal Menstruating Women (Phase 2): Interval From First Dose to Evidence of Ovulation.(Mean) = 2.67 Number of days (Standard Deviation, 1.53); Interval From First Dose to Evidence of Ovulation.(Mean) = 4.0 Number of days (Standard Deviation, 0)

These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.

Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Serplulimab (Approved; PD-1)

Company & Deal Intelligence context: Not reported

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.

Bottom line

JPRN-jRCT2031260297 is a focused lens on PD-L1 positive Gastroesophageal junction adenocarcinoma development. Its value will be determined by whether Serplulimab can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.